AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03606018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Mix 25
Description: insulin lispro biphasic in doses 0.4 ME/kg
Study NCT03606018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog® Mix 25
Description: insulin lispro biphasic in doses 0.4 ME/kg
Study NCT02285699 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SSRIs
Description: 12-weeks of standard SSRi treatment for those interested in Phase II of the study.
Study NCT03970330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 4.5mg daily dose, taken orally
Study NCT03883178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal-invasive endoscopic transgluteal approach
Description: Every patient, suffering from a pudendopathie or clunealgie, conform the Nantes criteria, and who are candidates for a surgical treatment through the transgluteal open approach, will be asked their permission to perform the procedure through a minimal-invasive endoscopic transgluteal approach.
Study NCT04265872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis
Description: injection into a vein
Study NCT01441336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
Study NCT02782000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lessons,long-term supervision and message
Study NCT02782000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lessons,short-term supervision and message
Study NCT03970330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone Acetate
Description: 5 - 15mg daily dose, taken orally
Study NCT03970330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norethindrone Acetate
Description: 5 - 15mg daily dose, taken orally
Study NCT03970330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily placebo pill, taken orally
Study NCT04220502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magic Shave Powder Gold
Description: Depilatory Cream for facial hair removal
Study NCT04220502 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional Shaving Methods
Description: Continued facial hair removal using traditional razors
Study NCT04058782 — intervention group
Intervention type: OTHER
Intervention: Imaging evaluation for vascular assessment
Description: At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
Study NCT03527875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PTBD group
Description: Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
Study NCT03527875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENBD group
Description: Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
Study NCT00911300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Description: Comparison of different drugs
Study NCT03556267 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: spinal needle
Description: It is a spinal needle with 'QUINCKE' Bevel. It is inserted in the lumbar region at the inter-space L4-L5, L4-L3 ,or L3-L2 lumber spaces, while the patient is put in the sitting position then CSF sample is taken then 2.5 ml of a local anesthetic(0.5 ml of 25 ug fentanyl and 2 ml of 8 mg heavy bupivacaine) is given intrathecal then the needle is withdrawn.
Study NCT03527875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBS group
Description: Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
Study NCT01652651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Can Succeed ICS
Description: ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
Study NCT02547974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A
Description: 2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
Study NCT02828098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: BO-112
Description: Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
Study NCT02828098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: BO-112
Description: BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year.
Study NCT02094066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
Study NCT02094066 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: serum physiologic
Description: preoperative 100 cc ıv serum physiologic
Study NCT04184674 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pneumotachograph
Description: Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures).
Study NCT04184674 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Esophageal catheter
Description: Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures).
Study NCT04184674 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transthoracic and / or transesophageal cardiac ultrasound
Description: The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults :~Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures).
Study NCT04184674 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrical impedance tomography (EIT) for pediatric patients
Description: For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.
Study NCT04987684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SCINSEV and PECAP
Description: To measure PECAP and SCINSEVs. To find whether electrodes are outside of the cochlear or within dead regions within the cochlear.
Study NCT02547974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A
Description: 2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
Study NCT02547974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A
Description: 2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
Study NCT02547974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
Study NCT04599543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL3 CAR T-cells
Description: Each subject receive IL3 CAR T-cells by intravenous infusion
Study NCT02511691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 18F-PSS232
Description: Diagnostic PET Tracer
Study NCT01200251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost eyelash gel
Description: Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
Study NCT02390167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONYX NEXT BGMS
Description: Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
Study NCT00911300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin-K-Antagonist
Description: Comparison of different drugs
Study NCT04447560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: One researcher will record the artery images as explained in the protocol and two researchers will measure the radius and area of those vessels separately. Researchers who are measuring the radius and area of vessels won't know whether those images belong to pre or post- ESP block. The results two researchers measure will be compared statistically and if there are no statistically significant differences, the mean value of their separate recordings will be taken into account for the statistical analysis.
Study NCT00248872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
Study NCT01656057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen dissolved in 50 ml of water
Study NCT01656057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin + acetaminophen dissolved in 50 ml of water
Study NCT01656057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam + acetaminophen dissolved in 50 ml of water
Study NCT01656057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cholecystokinin-8
Description: iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
Study NCT01656057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: iv. saline infusion 40 ml/hour for the first 60 minutes
Study NCT00355784 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: overfeeding
Description: overfeeding 2000kcals/day above energy requirements for 14d
Study NCT00355784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overfeeding
Description: overfeeding 2000kcals/day above energy requirements for 14d
Study NCT01933542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets identical to the chlorzoxazone tablets.
Study NCT01933542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorzoxazone
Description: Two 250 mg chlorzoxazone tablets
Study NCT01933542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
Study NCT01933542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
Study NCT01933542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
Study NCT01933542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zofran
Description: Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
Study NCT01126528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 35,000 IU per week, started at 26-29 weeks gestation, until delivery.
Study NCT01126528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
Study NCT04522635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (100 ml of Albumin 25%)
Description: single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
Study NCT00355784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone treatment
Description: growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
Study NCT01237977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A(Meditoxin®)
Description: single administration, Day 0, 20U
Study NCT01237977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A(Botox®)
Description: single administration, Day 0, 20U
Study NCT04072809 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This study does not involve any interventions.
Study NCT03264222 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Security screening procedure
Description: Screening procedure with security device (model QPS 100)
Study NCT04522635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: (100 ml of Albumin 25%)
Description: single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
Study NCT01452685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study NCT01452685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study NCT01452685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study NCT01452685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study NCT01452685 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Leuprorelin acetate
Description: TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
Study NCT03844620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive SOC
Study NCT03844620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Procedure
Description: Undergo ctDNA testing
Study NCT03844620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03844620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03844620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03844620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03844620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given by mouth
Study NCT03844620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Given by mouth
Study NCT03844620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given by mouth
Study NCT03844620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given by mouth
Study NCT02440191 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3DCRT
Description: conventional radiotherapy
Study NCT04881786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic forces
Description: 56g force and 224g force
Study NCT02552901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg ICG Dose
Description: least efficacious dose
Study NCT02552901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ICG dose
Description: per package insert
Study NCT02552901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg/kg ICG dose
Description: per package insert
Study NCT00564512 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Campath
Description: Fludarabine-Cyclophosphamide-Campath (FCCam)
Study NCT00564512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Fludarabine-Cyclophosphamide-Rituximab (FCR)
Study NCT00564512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
Study NCT00564512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
Study NCT00564512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
Study NCT03007602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Extremity Aerobic Exercise
Description: Range of maximal heart rate is being followed by a polar band during supervised session each week.~Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department.
Study NCT01574885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halotherapy
Description: The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
Study NCT00003126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
Study NCT02631486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Passive exercises, active exercises, strengthening, stretching
Study NCT02631486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Passive exercises, active exercises, strengthening, stretching
Study NCT02440191 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3DCRT
Description: conventional radiotherapy
Study NCT06401902 — intervention group
Intervention type: PROCEDURE
Intervention: carotid clamping
Description: Occurrence of consciousness perturbations, language difficulties and/or contralateral motor deficit during the carotid-clamping test and requiring shunt placement.
Study NCT02427412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
Study NCT02109172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208